We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
-11.59%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$13.6B
AUM Growth
-$3.29B
Cap. Flow
-$1.2B
Cap. Flow %
-8.83%
Top 10 Hldgs %
51.07%
Holding
116
New
14
Increased
50
Reduced
18
Closed
20

Top Buys

Rank Stock Value
1
TFCFA
Twenty-First Century Fox, Inc. Class A
TFCFA
+$538M
2
RHT
Red Hat Inc
RHT
+$426M
3
AABA
Altaba Inc
AABA
+$393M
4
CI icon
Cigna
CI
+$220M
5
EQIX icon
Equinix
EQIX
+$196M

Top Sells

Rank Stock Value
1
AET
Aetna Inc
AET
+$1.51B
2
ESRX
Express Scripts Holding Company
ESRX
+$1.13B
3
COL
Rockwell Collins
COL
+$584M
4
DELL icon
Dell
DELL
+$430M
5
EVHC
Envision Healthcare Holdings Inc
EVHC
+$257M

Sector Composition

Rank Sector Weight
1 Communication Services 23.71%
2 Healthcare 20.51%
3 Technology 18.84%
4 Industrials 7.34%
5 Consumer Discretionary 4.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TLRY icon
26
Tilray
TLRY
$666M
$162M 1.19%
247,952
– –
VRSK icon
27
Verisk Analytics
VRSK
$24.4B
$157M 1.15%
1,441,194
+16,641
+1% +$1.95M
CTXS
28
DELISTED
Citrix Systems Inc
CTXS
$150M 1.1%
1,468,234
-344,615
-19% -$36.4M
AZN icon
29
AstraZeneca
AZN
$257B
$148M 1.08%
1,942,500
+232,500
+14% +$18.2M
BABA icon
30
Alibaba
BABA
$286B
$144M 1.06%
1,050,000
+677,000
+182% +$100M
LBTYA icon
31
Liberty Global Class A
LBTYA
$3.63B
$127M 0.93%
5,972,437
-657,165
-10% -$16.1M
TSRO
32
DELISTED
TESARO, Inc.
TSRO
$126M 0.93%
+1,700,000
New +$81.7M
ARRS
33
DELISTED
ARRIS International plc Ordinary Shares
ARRS
$109M 0.8%
+3,580,000
New +$99.5M
LBTYK icon
34
Liberty Global Class C
LBTYK
$3.55B
$102M 0.75%
4,937,202
-2,054,438
-29% -$49.2M
ASND icon
35
Ascendis Pharma A/S
ASND
$16.6B
$93.9M 0.69%
1,499,297
+42,000
+3% +$2.64M
XLRN
36
DELISTED
Acceleron Pharma
XLRN
$91.5M 0.67%
2,100,000
+259,268
+14% +$13M
ARRY
37
DELISTED
Array Biopharma Inc
ARRY
$81.9M 0.6%
5,750,000
+625,000
+12% +$9.48M
MYOK
38
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$78.2M 0.57%
1,600,278
+69,000
+5% +$3.8M
ZGNX
39
DELISTED
Zogenix, Inc.
ZGNX
$74.8M 0.55%
2,050,500
+255,000
+14% +$10.4M
P
40
DELISTED
Pandora Media Inc
P
$74.5M 0.55%
+9,205,000
New +$79.5M
SRPT icon
41
Sarepta Therapeutics
SRPT
$1.98B
$69.8M 0.51%
640,000
+445,000
+228% +$55.7M
ENTA icon
42
Enanta Pharmaceuticals
ENTA
$392M
$65.5M 0.48%
925,000
+57,500
+7% +$4.41M
CVS icon
43
CVS Health
CVS
$119B
$60.9M 0.45%
+930,000
New +$69.4M
GBT
44
DELISTED
Global Blood Therapeutics, Inc.
GBT
$59.5M 0.44%
1,450,000
+80,000
+6% +$3M
MRTX
45
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$55.1M 0.4%
1,300,000
+425,000
+49% +$16.9M
IOVA icon
46
Iovance Biotherapeutics
IOVA
$3.76B
$50.7M 0.37%
5,725,000
+1,000,000
+21% +$9.64M
AMRN
47
Amarin Corp
AMRN
$298M
$47.6M 0.35%
175,000
+9,365
+6% +$3.41M
GRFS
48
Grifois
GRFS
$5.44B
$43.7M 0.32%
2,381,119
+591,119
+33% +$11.8M
NVCR icon
49
NovoCure
NVCR
$1.99B
$41.9M 0.31%
1,250,000
-100,000
-7% -$3.66M
ALNY icon
50
Alnylam Pharmaceuticals
ALNY
$31.6B
$40.1M 0.29%
550,000
+273,449
+99% +$21M
1
2
3 4 5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q4 2018 Portfolio in Review

As of Q4 2018, Thomas Steyer held 116 positions worth $13.6B, down 19% from $16.9B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Thomas Steyer withdrew a net $1.2B in Q4 2018, closing 20 positions and reducing 18 holdings. Its most notable exit was Aetna Inc, an estimated $1.51B position sold in full.

By sector, the portfolio is most concentrated in Communication Services at 24% of assets, up from 13% a quarter earlier, followed by Healthcare and Technology.

Against the trend, Thomas Steyer opened a new position in Red Hat Inc worth $472M.

  • Thomas Steyer's largest Q4 2018 buy was Red Hat Inc: 2,685,000 shares worth $472M.
  • Thomas Steyer added most to Twenty-First Century Fox, Inc. Class A in Q4 2018, an estimated $538M increase.
  • Thomas Steyer's biggest Q4 2018 reduction was Dell, cutting an estimated $430M.
  • Thomas Steyer fully exited Aetna Inc in Q4 2018, selling an estimated $1.51B.
  • Thomas Steyer's ten largest holdings make up 51% of its $13.6B portfolio in Q4 2018.
  • Thomas Steyer opened 14 new positions and closed 20 in Q4 2018.
  • Thomas Steyer's portfolio value fell 19% quarter-over-quarter to $13.6B.

Based on Farallon Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.